NDAINJECTIONINJECTABLEPriority Review
Approved
Nov 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
4/8 — Partial
Priority Review
TORADOL (ketorolac tromethamine) by Roche is clinical pharmacology pharmacodynamics ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (nsaid) that exhibits analgesic activity in animal models. Approved for pain, postoperative, cataracts, anterior chamber inflammation and 2 more indications. First approved in 1989.
Drug data last refreshed 18h ago
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacodynamics Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits analgesic activity in animal models. The mechanism of action of ketorolac, like that of other NSAIDs, is not completely understood but may be related to prostaglandin…
Worked on TORADOL at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.